November 1, 2022

Augmedit Closes Seed Investment Round

November 1, 2022

Augmedit, a Dutch startup that develops and brings to market Augmented Reality software for surgeons has closed a seed investment round of more than €1M with a consortium of Dutch and Swiss informal investors and the US based Venture Capital Fund Revere Partners.

Augmedit introduces a complete and intuitive Augmented Reality (AR) workflow for clinical practice. With their CE certified Lumi ™ software Augmedit automatically generates holograms out of medical imaging for surgical preparation and patient education. Their follow-on product LumiNE Elite projects these holograms on the patient in the operating room with a surgical plan to guide the surgeon. This holographic experience improves the insight of surgeons, making surgery safer and driving massive costs savings for medical institutions.

The funds will be used to obtain CE certification and FDA clearance of Augmedit’s beachhead products for neurosurgeons and to scaleup its technology to high volume / high impact indications beyond neurosurgery in both Europe and the USA.

Claartje Ypma, CEO Augmedit: “We are very excited to receive the support of multiple super angel investors and of Revere Partners VC. With Revere joining us, we expect to accelerate our market access in the US and use their knowhow and network for our future products in the field of oral surgery. Next to closing this financing round, also with the help of Money Meets Ideas, we have been granted €1.7M non-dilutive funding through the EIC Accelerator program. Therefore, we are well positioned to fulfill our ambition to become the leader in medical augmented reality applications.”

Jeremy Krell, Managing Partner Revere:”We believe that AR will soon become indispensable in the oral and maxillofacial health care industries. The Augmedit team has demonstrated the skillset and drive to create solutions that change the way surgeries are performed by providers, for the benefit of patients. Our investment and our network will help allow Augmedit to boost the value of AR solutions in the coming years.”

About Augmedit:

Augmedit was founded in 2018 by Tristan van Doormaal, neurosurgeon, Tom Mensink, Augmented Reality specialist and Claartje Ypma, MedTech entrepreneur. Augmedit’s mission is to provide safe, reliable, affordable, and easy to work with holograms. To prepare better individualized treatment plans. To collaborate towards more effective surgical procedures in unprecedented ways. To train medical staff and to visually engage and educate patients and their families.

To learn more visit or on LinkedIn.

About Revere Partners

Revere Partners is the first venture capital fund exclusively focused on oral health, identifying opportunities for investors and providing capital for cutting-edge technology innovations in the oral and systemic health sectors. Revere Partners’ inaugural fund has a flexible and unique structure with continuously open fundraising that also enables startups to connect with unrivaled industry resources and growth opportunities. Founded by Dr. Jeremy Krell and David Arena, Revere Partners fosters strategic partnerships that improve care delivery as well as patient and provider experiences – maximizing value for investors. Revere Partners is committed to inclusive partnerships with underserved businesses in the healthcare sector, including but not limited to, women-, minority and LBGTQ+-owned enterprises.

In addition to Krell and Arena, Revere Partners is backed by a world-renowned venture team, including former 13-year American Dental Association Executive Director Dr. Kathy O’Loughlin and dental technology pioneer Dr. Edward Zuckerberg. From its clinical merits, channel partnerships and growth strategy, Revere Partners is bringing the best oral and systemic health start-ups and the brightest founders to market by matching them with exceptional investors and industry experts.

To learn more visit or on LinkedIn.

For more information, please contact:

Claartje Ypma, CEO Augmedit

+31 617 1010 94

Go back
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.